Diabetes 52:957-964, 2003
© 2003 by the American Diabetes Association, Inc.
Prolonged Islet Allograft Survival in Diabetic NOD Mice by Targeting CD45RB and CD154
R. Damaris Molano1,
Antonello Pileggi1,
Thierry Berney1,
Raffaella Poggioli1,
Elsie Zahr1,
Robert Oliver1,
Camillo Ricordi1,
David M. Rothstein2,
Giacomo P. Basadonna2, and
Luca Inverardi1
1 Cell Transplant Center, Diabetes Research Institute, University of Miami School of Medicine, Miami, Florida
2 Department of Transplant Surgery, Yale Medical School, New Haven, Connecticut
Clinical islet transplantation is a successful procedure that can improve the quality of life in recipients with diabetes. A drawback of the procedure is the need for chronic administration of immunosuppressive drugs that, among other side effects, are potentially diabetogenic. Definition of immunosuppressive protocols that utilize nondiabetogenic compounds could further improve islet transplantation outcome. We used the NOD mouse to assess the effect of targeting the T-lymphocyte surface receptors CD45RB and CD154 in preventing loss of allogeneic islet grafts as a result of recurrence of autoimmunity and allorejection. Administration of the two antibodies led to significantly prolonged allograft survival, with a percentage of grafts surviving long-term. The therapeutic efficacy of the treatment was paralleled by a shift in CD45RB isoform expression on T-lymphocytes, increased in vitro responsiveness to interleukin-7, and increased in vitro -interferon production after anti-CD3 antibody stimulation. Furthermore, graft infiltration by CD8+ T-cells was remarkably reduced. Recipient mice bearing functioning allografts were otherwise immunocompetent, as assessed in vivo and in vitro by numerous tests, including intragraft cytokine production, responsiveness to polyclonal stimulation and alloantigens, and analysis of cell subset phenotype. These data show that nondiabetogenic regimens of immunomodulation can lead to prolonged islet allograft survival in the challenging NOD mouse model.

CiteULike Del.icio.us Digg Reddit Technorati What's this?
This article has been cited by other articles:

|
 |

|
 |
 
G. Vlad, V. D. D'Agati, Q.-Y. Zhang, Z. Liu, E. K. Ho, T. Mohanakumar, M. A. Hardy, R. Cortesini, and N. Suciu-Foca
Immunoglobulin-Like Transcript 3-Fc Suppresses T-Cell Responses to Allogeneic Human Islet Transplants in hu-NOD/SCID Mice
Diabetes,
July 1, 2008;
57(7):
1878 - 1886.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
S. S. Lee, W. Gao, S. Mazzola, M. N. Thomas, E. Csizmadia, L. E Otterbein, F. H. Bach, and H. Wang
Heme oxygenase-1, carbon monoxide, and bilirubin induce tolerance in recipients toward islet allografts by modulating T regulatory cells
FASEB J,
November 1, 2007;
21(13):
3450 - 3457.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
A. Goldberg, M. Parolini, B. Y. Chin, E. Czismadia, L. E. Otterbein, F. H. Bach, and H. Wang
Toll-like receptor 4 suppression leads to islet allograft survival
FASEB J,
September 1, 2007;
21(11):
2840 - 2848.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
H. Wang, S. S. Lee, C. Dell'Agnello, V. Tchipashvili, J. D'Avilla, E. Czismadia, B. Y. Chin, and F. H. Bach
Bilirubin Can Induce Tolerance to Islet Allografts
Endocrinology,
February 1, 2006;
147(2):
762 - 768.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
T. Pearson, P. Weiser, T. G. Markees, D. V. Serreze, L. S. Wicker, L. B. Peterson, A.-M. Cumisky, L. D. Shultz, J. P. Mordes, A. A. Rossini, et al.
Islet Allograft Survival Induced by Costimulation Blockade in NOD Mice Is Controlled by Allelic Variants of Idd3
Diabetes,
August 1, 2004;
53(8):
1972 - 1978.
[Abstract]
[Full Text]
[PDF]
|
 |
|
Copyright © 2003 by the American Diabetes Association.
|
|
| |
|